We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
Exclusively sourcing our pipeline through external innovation, we have no internal competing pipeline as we recognize the best science is delivered in biotech and academic institutions. We are proud our team comprises talents attracted from Pharma, biotech and academia, to drive shared success through creative collaborations.
ONCOLOGY
Where we plan to expand
Solid tumors & hematology
- Precision medicine approaches
- BIC/FIC with strong science and meaningful differentiation
Smaller patient segments attractive for mid-sized companies
RARE DISEASE
Where we plan to expand
High unmet needs in underserved rare diseases
Drive liver & bone franchises; expand to new disease areas
Good fit for clinical development & go-to-market model
NEUROSCIENCE
Where we plan to expand
Rare neuroscience
Expand beyond neurotoxins in non-rare to adjacent areas
Strong innovation & scientific advances
Partnering with Ipsen
As a mid-size pharma, we leverage our agility, R&D capabilities and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience and global reach to accelerate innovation to bring new medicines to patients.
At Ipsen, we believe great partnerships create great possibilities. Data is just the beginning; we go beyond this to translate the clinical benefit into true patient impact. We focus on how one patient will have an enhanced experience because of each innovation and unite expertise to deliver this.
Pipeline
Our robust development pipeline, backed by our expertise and external-innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease and Neuroscience.
Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
Paris and Montréal, 25 February 2019 – Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced that they have entered into an agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset palovarotene, an investigational…
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators…
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45…
Ipsen to acquire Epizyme, expanding its portfolio in oncology
PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by…
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.
April 9, 2019 at 12:29 PM EDT
Science-First Collaborations: Ipsen’s Blueprint to External Innovation
David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration,…
Financial results for the first nine months of 2024
The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.
Financial results for the first half of 2024
The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.
Our 2023 Integrated Annual Report is live!
In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.
Navigating Proactive Sustainability in Pharma R&D and Partnering
In March, we were proud to see Florence Dal Degan, Senior Director of External Innovation, participate in a panel discussion with different stakeholders, from consulting firms, pharma companies, investors to startups at BioEurope Spring entitled “Towards a Greener Globe: Biopharma’s Path to Sustaina
Q1 2024 sales update
The Q1 2024 sales announcement will be published on April 24, 2024 at 7am CET. Find out more and register for the conference call for investors and analysts.
Unlocking Potential Through Early-Stage Partnerships
We are pleased to share a recent conversation with Mary Jane Hinrichs, Senior Vice President, and Global Head of Early Development. Mary Jane spearheads the strategic direction and execution of early-stage programs at Ipsen, guiding them from drug candidate to…
Applications now open for the 2024 Golden Ticket competition
As part of our commitment to accelerating transformative research and development, we’re excited to announce that our annual Golden Ticket competition is now open! Through our continued partnership with BioLabs, we’re delighted to be offering the brightest minds in biotech…
Focus; Confidence; Commitment – The Building Blocks of Win-Win Partnerships
Ipsen’s Senior Director of Global Partnering for Oncology, Madee Gooriah, is part of the team leading efforts to expand Ipsen’s oncology franchise through external partnerships at every stage of development. But in an industry marked by complexity, how do we…
FY 2023 results announcement
Ipsen’s FY 2023 results announcement took place on 8 February 2024 at 7am CET/1am EST.